Abstract Library

#2815 Unexpected High Rate of Metastases in Type 1 Gastric Neuroendocrine Neoplasia

Introduction: Gastric neuroendocrine neoplasms (gNEN) represent about 7.5% of gastroenteropancreatic NEN (gepNEN), classified in: type 1 (70-80%), related to autoimmune gastritis, type 2 (5%), related to Zollinger-Ellison syndrome in multiple endocrine neoplasia 1 and type 3 (15-20%), in absence of hypergastrinemia or mucosal atrophy.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Bottiglieri F, Modica R, de Cicco F, Minotta R, Faggiano A,

Keywords: gastric, neuroendocrine, type1, type3, metastases,

#2691 Somatostatin Analogs in Patients with Zollinger Ellison Syndrome (ZES): An Observational Study

Introduction: Zollinger Ellison syndrome (ZES) is a rare syndrome caused by gastrin hypersecretion from a primary neuroendocrine tumor (NET), usually located within the duodenum or into the pancreas. Gastrinomas have two important treatment goal: the control of the gastrin-excess state and the control of tumor growth.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: massironi s

Authors: Massironi S, Peracchi M, Elvevi A, Cristoferi L, Quatrini M,

Keywords: ZES, gastrinoma, somatostatin analogs,

#2191 Endocrine Paraneoplastic Syndromes in Patients with Neuroendocrine Neoplasms

Introduction: Endocrine paraneoplastic syndromes (ePNS) result from production of bioactive substances from tumours not related to their expected tissue of origin. Neuroendocrine neoplasms (NENs) have been associated with ectopic secretion of several hormones, but the prevalence of ePNS has only been described in a small number of studies.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Chatzellis E, Alexandraki K, Angelousi A, Tsoli M, Kaltsatou M,

Keywords: paraneoplastic syndromes, neuroendocrine neoplasms, ectopic secretion,

#2005 Incidence and Prevalence of Neuroendocrine Tumors in England

Introduction: Historically the incidence and prevalence of neuroendocrine tumours (NETs) has been difficult to establish. Studies by Ellis et al in 2006 estimated the incidence of gastroenteropancreatic neuroendocrine tumours (GEP NETs) to be 1.3 per 100,000 per year (incidence hereafter given as cases per 100,000). However, the SEER USA data suggests a four-fold higher incidence, and prevalence of 35 per 100,000.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Genus T

Authors: Genus T, Bouvier C, Wong K, Srirajaskanthan R, Rous B,

Keywords: Neuroendocrine cancer, prevalence, incidence,

#1935 Prevalence of Pancreatic Neuroendocrine Neoplasms with Serotonin Secretion

Introduction: Pancreatic neuroendocrine neoplasms (pNENs) are rare neoplasms and represent 1-2% of all pancreatic neoplasms. These tumors can secrete a variety of hormonally active substances producing distinct clinical symptoms, or can be clinically non-functioning. Pancreatic NENs that secrete serotonin are extremely rare, but their prevalence has not been explored adequately.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Tsoukalas N

Authors: Tsoukalas N, Alexandraki K, Mavroeidi V, Chatzellis E, Tsoli M,

Keywords: serotonin-producing pNEN, 5-HIAA, prognosis,